CA
HUMA icon

Clearstead Advisors’s Humacyte HUMA Stock Holding History

Clearstead Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103 Buy
+130
New +$120 ﹤0.01% 3351
2025
Q3 		– Sell
-7
Closed -$15 – 3158
2025
Q2 		$15 Buy
+7
New +$13 ﹤0.01% 2716

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Clearstead Advisors's HUMA Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Humacyte (HUMA) in Q2 2026: 130 shares worth $103. The stake represents ﹤0.01% of the portfolio and ranks #3351 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in HUMA as recently as Q2 2025.

Clearstead Advisors first reported a position in HUMA in Q2 2025 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Clearstead Advisors held 130 shares of Humacyte worth $103 as of Q2 2026.
  • Humacyte was a new Clearstead Advisors position in Q2 2026.
  • Humacyte made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3351 holding.
  • Clearstead Advisors first reported a position in Humacyte in Q2 2025 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.